摘要:
Preconcentrates comprising a fatty acid oil mixture and at least one surfactant, and methods and uses thereof are disclosed. The preconcentrates are capable of forming a self-nanoemulsifying drug delivery system (SNEDDS), a self-microemulsifying drug delivery system (SMEDDS), or self-emulsifying drug delivery systems (SEDDS) in an aqueous solution.
摘要:
Novel capsules where an outer shell comprises a polysaccharide, e.g. an alginate. In the capsules there is an emulsion comprising a fatty acid oil mixture and at least one surfactant. Preferred fatty acid oils are eicosapentaenoic acid (EPA) and doccosahexaenoic acid (DHA).
摘要:
The present invention relates to a process for preparing compositions of high concentrations of omega-3 fatty acids from krill. Furthermore, the invention relates to a composition comprising high concentrations of omega-3 fatty acids, and a lipid fraction from krill comprising high amounts of fatty acids with chain length C14 and C16.
摘要:
The present invention relates to lipid compounds of the general formula (I):
wherein R 1 is selected from a C 10 -C 22 alkyl, a C 10 -C 22 alkenyl having 1-6 double bonds, and a C 10 -C 22 alkynyl having 1-6 triple bonds;R 2 and R 3 are the same or different and may be selected from a group of different substituents; and X represents a carboxylic acid or a derivative thereof, such as a carboxylic ester, a carboxylic anhydride or a carboxamide; or a pharmaceutically acceptable salt, solvate, solvate of such salt or a prodrug thereof. The invention also relates to pharmaceutical compositions and lipid compositions comprising such compounds, and to such compounds for use as medicaments or for use in therapy, in particular for the treatment of diseases related to the cardiovascular, metabolic and inflammatory disease area.
摘要:
The present invention relates to lipid compounds of the general formula (I): wherein • R1 is selected from a C10-C21 alkyl, a C10-C21 alkenyl having 1-6 double bonds, and a C10-C21 alkynyl having 1-6 triple bonds; • R2 and R3 are the same or different and are selected from hydrogen and a C1-C6 alkyl group; and X is selected from O, S, SO, SO2, Si or Se; • n = 1 or 3; and • P1 is selected from a hydrogen, a C10-C21 alkyl, a C10-C21 alkenyl having 1-6 double bonds, and a C10-C21 alkynyl having 1-6 triple bonds, optionally substituted; or P1 is represented by: wherein P2, P3 and P4 are selected from a hydrogen, an alkyl, alkenyl, alkynyl, optionally substituted; or P1 is a phosphonate or a phosphate ester, represented by or P1 is a sulphonate or a sulphate ester, represented by wherein P5 is a hydrogen or a C1-C6 alkyl; or a pharmaceutically acceptable salt, complex or solvate thereof. Also disclosed are pharmaceutical compositions and lipid compositions comprising such compounds, and such compounds for use as medicaments, in particular for the treatment of diseases related to the cardiovascular, metabolic and inflammatory disease area.
摘要:
The invention relates to a process for decreasing the amount of environmental pollutants in a mixture comprising a fat or an oil, being edible or for use in cosmetics, the fat or oil containing the environmental pollutants, which process comprises the steps of adding a volatile working fluid to the mixture, where the volatile working fluid comprises at least one of a fatty acid ester, a fatty acid amide, a free fatty acid and a hydrocarbon, and subjecting the mixture with the added volatile working fluid to at least one stripping processing step, in which an amount of environmental pollutant present in the fat or oil, being edible or for use in cosmetics, is separated from the mixture together with the volatile working fluid. The present invention also relates to a volatile environmental pollutants decreasing working fluid, for use in decreasing an amount of environmental pollutants present in a fat or oil, being edible or for use in cosmetics. In addition, the present invention relates to a health supplement, a pharmaceutical and an animal feed product prepared according to the process mentioned above.
摘要:
The invention is directed to the use of the n-3 PUFA EPA and/or DHA in the preparation of an oral medicament for preventing cerebral damage in patients having symptoms of atherosclerosis of arteries supplying the brain.
摘要:
Disclosed is a prophylactic or therapeutic agent for ulcerative colitis, Crohn's disease and/or Behcet's disease. The therapeutic agent comprises a highly unsaturated fatty acid derivative represented by the formula (1) as an active ingredient.